GSK acquires Reliant in move to boost cardio franchise
In a move to bolster its cardiovascular product line, GlaxoSmithKline (GSK) has announced plans to purchase New Jersey-based Reliant Pharmaceuticals for $1.65 billion in cash.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.